HUMIRA^® Pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab

References

• Weisman MH, Moreland LW, Furst DE et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin. Ther.25, 1700–1721 (2003).
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet358, 903–911 (2001).
   PubMed Web of Science ®Google Scholar
• Lipsky PE. Rheumatoid arthritis. In: Harrison’s Principles of Internal Medicine (16th Edition). Kasper DL, Braunwald E, Fauci AS et al. (Eds). [Harrison’s Online]. McGraw-Hill, NY, USA 1968–1977 (2005).
   Google Scholar
• Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health3, 243–252 (2000).
   PubMedGoogle Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum.48, 35–45 (2003).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Keystone EC, Furst DE et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann. Rheum. Dis.65, 753–759 (2006).
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum.50, 1400–1411 (2004).
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54, 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Schiff MH, Burmester GR, Kent JM et al. Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis.65, 889–894 (2006).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Cifaldi MA et al. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis.66(2), 163–168 (2007).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52, 3279–3289 (2005).
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum.54(7), 2136–2146 (2006).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol.55, 598–606 (2006).
   PubMed Web of Science ®Google Scholar
• Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res. Ther.6(Suppl. 2), S19–S23 (2004).
   Google Scholar
• WHONoncommunicable diseases and mental health – adherence to longterm therapies: policy for action. Meeting Report 4–5 June, 2001. Geneva, Switzerland WHO/MNC/CCH/01.02 (2001).
   Google Scholar
• Lipsky P, van der Heijde D, St Clair E et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: antitumor necrosis factor trial in rheumatoid arthritis with concomitant therapy group. N. Engl. J. Med.343, 1594–1602 (2000).
   PubMed Web of Science ®Google Scholar
• Maini R, Breedveld F, Kalden J et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum.50, 1051–1065 (2004).
   PubMed Web of Science ®Google Scholar
• St Clair E, Desiree M, van der Heijde D et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum.50, 3432–3443 (2004).
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager J et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet363, 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• Genovese M, Bathon J, Martin R et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcomes. Arthritis Rheum.46, 1443–1450 (2002).
   PubMed Web of Science ®Google Scholar
• Korytkowski M, Bell D, Jacobson C, Suwannasari R, for the FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin. Ther.23, 2836–2848 (2003).
   Google Scholar
• Niskanen L, Jensen LE, Råstam J et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin. Ther.26, 531–540 (2004).
   PubMed Web of Science ®Google Scholar
• Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin. Ther.26, 1498–1505 (2004).
   PubMed Web of Science ®Google Scholar
• Gobel H, Baar H, Beikufner HD et al. Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan. Headache38, 267–269 (1998).
   PubMedGoogle Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J, Rebiject Study Group. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon β-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult. Scler.11(5), 585–591 (2005).
   PubMed Web of Science ®Google Scholar
• Stanhope R, Albanese A, Moyle L, Hamill G. Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an auto injector and a pen injection system. Arch. Dis. Child.67, 994–997 (1992).
   PubMed Web of Science ®Google Scholar
• Gold DT, Pantos BS, Masica DN, Misurski DA, Marcus R. Initial experience with teriparatide in the United States. Curr. Med. Res. Opin.22(4), 703–708 (2006).
   PubMed Web of Science ®Google Scholar
• Kivitz A, Cohen S, Dowd JE et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen vs. a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH study. Clin. Ther.28(10), 619–629 (2006).
   PubMedGoogle Scholar
• Ritter PL, Gonzalez, VM, Laurent DD, Lorig KR. Measurement of pain using the visual numeric scale. J. Rheumatol.33, 574–580 (2006).
   PubMed Web of Science ®Google Scholar
• Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti–tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid arthritis). J. Rheumatol.30, 2563–2571 (2003).
   PubMed Web of Science ®Google Scholar